-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

What's Next for Patients with 2L+ Relapsed or Refractory Multiple Myeloma?

Sponsor: Johnson & Johnson
Program: Product Theaters
Hematology Disease Topics & Pathways:
Treatment Considerations, Non-Biological therapies
Monday, December 9, 2024: 12:15 PM-1:15 PM
Room 3 (San Diego Convention Center)
Speaker:
Deepu Madduri, MD, Johnson & Johnson
Disclosures:
No relevant conflicts of interest to declare.

This presentation is intended for U.S. based registered meeting attendees

For in-person participants only
See more of: Product Theaters
<< Previous Product Theater | Next Product Theater >>